Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Investing.com - Mizuho has reiterated an Outperform rating and $85.00 price target on Tectonic Therapeutics Inc. (NASDAQ:TECX), currently trading at $16.09 with a market cap of $301M, ahead of upcoming clinical trial data for the company’s TX45 drug candidate. The Strong Buy consensus among analysts, with targets ranging from $64 to $101, reflects significant upside potential.
The research firm expects Tectonic to present Phase 1b (Part B) hemodynamic data for TX45 in pulmonary hypertension patients with heart failure with reduced ejection fraction (PH-HFrEF) in early fourth quarter of 2025.
Mizuho anticipates the hemodynamic effects for TX45 in PH-HFrEF patients will move in the same direction as previously observed in patients with pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) in Part A of the trial, where key measurements showed meaningful improvements.
The firm projects "positive Part B data, with clinically meaningful hemodynamic improvements of 15-20% for PCWP and 15-20% for PVR in patients with CpcPH as well as potentially meaningful CO and SVR improvements for PH-HFrEF patients."
With TECX shares trading just $2-3 above cash value, Mizuho believes "the potential blockbuster opportunity for TX45 in HFpEF remains significantly underappreciated and no value for PH-HFrEF is in the stock." According to InvestingPro analysis, TECX appears undervalued, with 6 additional ProTips available to subscribers for deeper insight into the company’s financial health and growth potential.
In other recent news, Tectonic Therapeutics has caught the attention of two research firms with positive analyst ratings. Oppenheimer initiated coverage on Tectonic Therapeutics with an Outperform rating, setting a price target of $80.00. The firm highlighted the potential of Tectonic’s lead asset, TX45, in treating cardiovascular disorders, particularly for patients with PH-HFpEF, a condition affecting about 1.4 million individuals in the United States. Similarly, Truist Securities began coverage with a Buy rating and a price target of $64.00. Truist pointed to the significant upside potential of TX45, which is being developed as a relaxin-based treatment for Group 2 pulmonary hypertension with heart failure with preserved ejection fraction. These recent developments reflect growing optimism among analysts regarding Tectonic Therapeutics’ prospects in the medical field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.